Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS (Details Narrative)

v3.3.1.900
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 21, 2015
Dec. 20, 2013
Aug. 31, 2014
Nov. 30, 2015
Nov. 30, 2014
Nov. 30, 2015
Nov. 30, 2014
Feb. 28, 2015
Amortization of deferred compensation cost       $ 7,000 $ 7,000 $ 21,000 $ 72,750  
Accrued expenses       434,117   434,117   $ 304,041
Independent Directors ( Dr. Mark Baker, Mr. Mark Pastreich, Mr. Arthur Radin and Mr. Cyril Narishkin) [Member]                
Description of payment terms

Paid quarterly half in cash and half in common stock.

             
Annually compensation paid $ 25,000              
Consulting Agreement [Member] | Mr. Cyril Narishkin [Member]                
Monthly payment for agreement $ 16,000              
Description of payment terms

Half is to be paid in cash and half is to be paid in shares of common stock.

             
Annually additional payment for agreement $ 25,000              
Accrued expenses       12,500   12,500    
Dr. Paul Mark Baker [Member] | Clinical Research & Support Services Consulting Agreement (FREEDOM60 Syringe Infusion System) [Member]                
Share price (in dollars per share)   $ 0.20            
Dr. Paul Mark Baker [Member] | Clinical Research & Support Services Consulting Agreement (FREEDOM60 Syringe Infusion System) [Member]                
Number of shares issued upon agreement   420,000            
Agreement term   3 years            
Bonus paid to officer     $ 25,000          
Mr.Andrew Sealfon [Member] | Aircraft [Member]                
Lease payments       $ 5,375 $ 5,375 $ 16,125 $ 16,125